{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:37:10Z","timestamp":1775219830739,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T00:00:00Z","timestamp":1281571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Nail psoriasis occurs in up to half of psoriatic patients and can lead to significant physical impairment and pain. To date, patients and clinicians are actually dissatisfied by current therapeutic approaches.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> Our main aim is to evaluate Infliximab efficacy in nail psoriasis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> We performed an open\u2010label and uncontrolled retrospective study considering all psoriatic patients presenting recalcitrant nail involvement and receiving Infliximab in our Department during the period between January 2008 and March 2009. We calculated nail psoriasis severity index (NAPSI) score at 0, 14, 22 and 38\u2003weeks and percentage of patients achieving NAPSI\u201050,\u201075,\u201090 at 14, 22 and 38\u2003weeks.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> We observed a rapid nail improvement in most cases after 22\u2003weeks of Infliximab therapy, but a complete nail clearing was reached in only five (10.4%) patients. We don\u2019t have a follow\u2010up longer than 38\u2003weeks to assess long\u2010term efficacy of this treatment in nail psoriasis.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Infliximab, in our experience, has proved to be effective in reducing nail lesions and, in some cases, even clearing them. Our data demonstrate long\u2010term efficacy of this biological agent in nail psoriasis.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2010.03826.x","type":"journal-article","created":{"date-parts":[[2010,8,13]],"date-time":"2010-08-13T00:15:28Z","timestamp":1281658528000},"page":"549-553","source":"Crossref","is-referenced-by-count":33,"title":["Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients"],"prefix":"10.1111","volume":"25","author":[{"given":"C","family":"Fabroni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Troiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Lotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30876-3"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1996.d01-1035.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08686.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00112.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02738.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"issue":"0","key":"e_1_2_5_8_2","first-page":"5","article-title":"European S3\u2010Guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana D","year":"2009","journal-title":"J Eur Acad Dermatol Venereol, Oct"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.042"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.012"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24172"},{"issue":"0","key":"e_1_2_5_13_2","first-page":"9","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23","author":"McGonagle D","year":"2009","journal-title":"JEADV"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802653198"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2010.03826.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2010.03826.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T17:23:28Z","timestamp":1697390608000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2010.03826.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,12]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1111\/j.1468-3083.2010.03826.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03826.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,12]]}}}